{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:22Z","timestamp":1753892062240,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Signet ring-like cell prostate cancer is a rare and highly aggressive histological subtype of prostate cancer. The characteristic feature is that the cancer cells produce a large amount of mucin. This mucin gradually accumulates within the cells, pushing the nucleus to one side and giving the cells a signet-ring-like appearance. Late-stage prostate cancer typically metastasizes to bones, lungs, and other organs via lymphatic or hematogenous routes. Rectal involvement with gastrointestinal symptoms as the initial presenting manifestation is relatively uncommon. This case report aims to describe the diagnostic process of prostate cancer in an 82-year-old male patient. The initial symptom was diarrhea, the admission diagnosis was rectal malignancy, and the diagnostic clue was the presence of signet-ring cells. The tumor origin analysis was conducted alongside serological and imaging examinations. Furthermore, this report discusses the endoscopic manifestations, pathomorphological changes, and clinical prognostic analysis of this prostate cancer case, to enhance the recognition of rare pathological subtypes of prostate cancer.<\/jats:p>","DOI":"10.3389\/fonc.2025.1516220","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:45Z","timestamp":1748232645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Signet-ring cell carcinoma in rectal malignancies: a case report with an unexpected outcome"],"prefix":"10.3389","volume":"15","author":[{"given":"Aichun","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12967-020-02281-4","article-title":"Data-driven translational prostate cancer research: from biomarker discovery to clinical decision","volume":"18","author":"Lin","year":"2020","journal-title":"J Transl Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"121659","DOI":"10.1016\/j.lfs.2023.121659","article-title":"Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis","volume":"325","author":"Cheng","year":"2023","journal-title":"Life Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"107932","DOI":"10.1016\/j.pharmthera.2021.107932","article-title":"Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics","volume":"228","author":"Adamaki","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2023.06.012","article-title":"MR imaging-guided prostate cancer therapies","volume":"62","author":"Adamo","year":"2024","journal-title":"Radiol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3390\/ijms22073753","article-title":"Hereditary prostate cancer: genes related, target therapy and prevention","volume":"22","author":"Vietri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/ijms22041551","article-title":"Treating prostate cancer by antibody-drug conjugates","volume":"22","author":"Rosellini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12508","DOI":"10.3390\/ijms241512508","article-title":"Can we predict prostate cancer metastasis based on biomarkers? Where are we now","volume":"24","author":"San Francisco","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"122270","DOI":"10.1016\/j.lfs.2023.122270","article-title":"Molecular heterogeneity in prostate cancer and the role of targeted therapy","volume":"336","author":"Khan","year":"2024","journal-title":"Life Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01496-5","article-title":"Molecular tracing of prostate cancer lethality","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_827_21","article-title":"Primary signet ring cell carcinoma of prostate: A rare case report and review of literature","volume":"19","author":"Gupta","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/medicina60060877","article-title":"Prostate adenocarcinoma with signet-ring cells and features of mucin: A clinical case and literature review","volume":"60","author":"Sakalauskaite","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/jpm13061016","article-title":"A case of prostatic signet-ring cell-like carcinoma with pagetoid spread and intraductal carcinoma and long-term survival: PD-L1 and mismatch repair system proteins (MMR) immunohistochemical evaluation with systematic literature review","volume":"13","author":"Koufopoulos","year":"2023","journal-title":"J Pers Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/his.14711","article-title":"WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer","volume":"81","author":"Kench","year":"2022","journal-title":"Histopathology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 world health organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.32074\/1591-951X-822","article-title":"Prostate pathology: what is new in the 2022 WHO classification of urinary and male genital tumors","volume":"115","author":"Surintrspanont","year":"2022","journal-title":"Pathologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.030","article-title":"Re: WHO classification of tumours, 5th edition, volume 8: urinary and male genital tumours","volume":"84","author":"Tateo","year":"2023","journal-title":"Eur Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00580-7","article-title":"Germline testing and genetic counselling in prostate cancer","volume":"19","author":"Russo","year":"2022","journal-title":"Nat Rev Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-654","article-title":"A case report of primary signet ring cell carcinoma of the lung: imaging study and literature review","volume":"10","author":"Yang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000685","article-title":"Germline mutations of B-Raf proto-oncogene and pathological implications in prostate cancer: observational study","volume":"85","author":"Tiabi","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13578-022-00950-z","article-title":"SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF","volume":"12","author":"Feng","year":"2022","journal-title":"Cell Biosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1393","article-title":"Unique spectrum of activating BRAF alterations in prostate cancer","volume":"29","author":"Chehrazi-Raffle","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0314-z","article-title":"The diverse roles of SPOP in prostate cancer and kidney cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2021.0416","article-title":"Silencing ACTG1 expression induces prostate cancer epithelial mesenchymal transition through MAPK\/ERK signaling pathway","volume":"40","author":"Xiao","year":"2021","journal-title":"DNA Cell Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1516220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:46Z","timestamp":1748232646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1516220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1516220"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1516220","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1516220"}}